177 related articles for article (PubMed ID: 20051879)
1. Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition.
Connelly MA; Parry TJ; Giardino EC; Huang Z; Cheung WM; Chen C; Cools F; Van der Linde H; Gallacher DJ; Kuo GH; Sarich TC; Demarest KT; Damiano BP
J Cardiovasc Pharmacol; 2010 May; 55(5):459-68. PubMed ID: 20051879
[TBL] [Abstract][Full Text] [Related]
2. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.
Vergeer M; Bots ML; van Leuven SI; Basart DC; Sijbrands EJ; Evans GW; Grobbee DE; Visseren FL; Stalenhoef AF; Stroes ES; Kastelein JJ
Circulation; 2008 Dec; 118(24):2515-22. PubMed ID: 19029469
[TBL] [Abstract][Full Text] [Related]
3. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.
Barter P
Am J Cardiol; 2009 Nov; 104(10 Suppl):10E-5E. PubMed ID: 19895939
[TBL] [Abstract][Full Text] [Related]
4. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?
Neeli H; Rader DJ
Cardiol Clin; 2008 Nov; 26(4):537-46. PubMed ID: 18929230
[TBL] [Abstract][Full Text] [Related]
5. Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure.
Blasi E; Bamberger M; Knight D; Engwall M; Wolk R; Winter S; Betts A; John-Baptiste A; Keiser J
J Cardiovasc Pharmacol; 2009 Jun; 53(6):507-16. PubMed ID: 19455053
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.
Yvan-Charvet L; Matsuura F; Wang N; Bamberger MJ; Nguyen T; Rinninger F; Jiang XC; Shear CL; Tall AR
Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1132-8. PubMed ID: 17322101
[TBL] [Abstract][Full Text] [Related]
7. Spotlight on HDL-raising therapies: insights from the torcetrapib trials.
Kontush A; Guérin M; Chapman MJ
Nat Clin Pract Cardiovasc Med; 2008 Jun; 5(6):329-36. PubMed ID: 18431367
[TBL] [Abstract][Full Text] [Related]
8. HDL metabolism and CETP inhibition.
Barkowski RS; Frishman WH
Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility.
Kalgutkar AS; Frederick KS; Hatch HL; Ambler CM; Perry DA; Garigipati RS; Chang GC; Lefker BA; Clark RW; Morehouse LA; Francone O; Hu X
Xenobiotica; 2014 Jul; 44(7):591-605. PubMed ID: 24380613
[TBL] [Abstract][Full Text] [Related]
10. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
Shinkai H
Expert Opin Ther Pat; 2009 Sep; 19(9):1229-37. PubMed ID: 19663630
[TBL] [Abstract][Full Text] [Related]
11. [Torcetrapib increases mortality in patients with a high risk of cardiovascular disorders].
Rensen PC; Jukema JW
Ned Tijdschr Geneeskd; 2008 May; 152(19):1088-90. PubMed ID: 18552062
[TBL] [Abstract][Full Text] [Related]
12. Where are we with high-density lipoprotein raising and inhibition of cholesteryl ester transfer for heart disease risk reduction?
Schaefer EJ; Asztalos BF
Curr Opin Cardiol; 2007 Jul; 22(4):373-8. PubMed ID: 17556892
[TBL] [Abstract][Full Text] [Related]
13. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition.
Hu X; Dietz JD; Xia C; Knight DR; Loging WT; Smith AH; Yuan H; Perry DA; Keiser J
Endocrinology; 2009 May; 150(5):2211-9. PubMed ID: 19164467
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels.
Clerc RG; Stauffer A; Weibel F; Hainaut E; Perez A; Hoflack JC; Bénardeau A; Pflieger P; Garriz JM; Funder JW; Capponi AM; Niesor EJ
J Hypertens; 2010 Aug; 28(8):1676-86. PubMed ID: 20498617
[TBL] [Abstract][Full Text] [Related]
15. Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms.
Sofat R; Hingorani AD; Smeeth L; Humphries SE; Talmud PJ; Cooper J; Shah T; Sandhu MS; Ricketts SL; Boekholdt SM; Wareham N; Khaw KT; Kumari M; Kivimaki M; Marmot M; Asselbergs FW; van der Harst P; Dullaart RP; Navis G; van Veldhuisen DJ; Van Gilst WH; Thompson JF; McCaskie P; Palmer LJ; Arca M; Quagliarini F; Gaudio C; Cambien F; Nicaud V; Poirer O; Gudnason V; Isaacs A; Witteman JC; van Duijn CM; Pencina M; Vasan RS; D'Agostino RB; Ordovas J; Li TY; Kakko S; Kauma H; Savolainen MJ; Kesäniemi YA; Sandhofer A; Paulweber B; Sorli JV; Goto A; Yokoyama S; Okumura K; Horne BD; Packard C; Freeman D; Ford I; Sattar N; McCormack V; Lawlor DA; Ebrahim S; Smith GD; Kastelein JJ; Deanfield J; Casas JP
Circulation; 2010 Jan; 121(1):52-62. PubMed ID: 20026784
[TBL] [Abstract][Full Text] [Related]
16. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
Niesor EJ
Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels.
Davidson MH; McKenney JM; Shear CL; Revkin JH
J Am Coll Cardiol; 2006 Nov; 48(9):1774-81. PubMed ID: 17084249
[TBL] [Abstract][Full Text] [Related]
18. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction.
Schaefer EJ; Asztalos BF
Am J Cardiol; 2007 Dec; 100(11 A):n25-31. PubMed ID: 18047849
[TBL] [Abstract][Full Text] [Related]
19. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin.
de Haan W; de Vries-van der Weij J; van der Hoorn JW; Gautier T; van der Hoogt CC; Westerterp M; Romijn JA; Jukema JW; Havekes LM; Princen HM; Rensen PC
Circulation; 2008 May; 117(19):2515-22. PubMed ID: 18458167
[TBL] [Abstract][Full Text] [Related]
20. Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice.
Hansen MK; McVey MJ; White RF; Legos JJ; Brusq JM; Grillot DA; Issandou M; Barone FC
J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):196-202. PubMed ID: 20332533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
